Long-term Safety and Efficacy of Corneal Collagen Crosslinking in a Pediatric Group With Progressive Keratoconus: A 7-year Follow-up

Polido, Júlia; Araújo, Maria Emília Xavier dos Santos; Wakamatsu, Tais Hitomi; Alexander, João Gabriel; Cabral, Thiago; Ambrósio, Renato; Freitas, Denise de

doi:10.1016/j.ajo.2023.01.012

Cited by 5 publications

(9 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Five studies listed post-CXL progression criteria, including an increase in Kmax of at least 1 or 1.5 D at the most recent follow-up. Progression rates ranged from 10.8 to 24% [21,32 ▪▪ ,57–59], and were overall generally higher than in the adult studies. UDVA significantly improved in three studies [32 ▪▪ ,55,58], while no significant change was noted in an additional three [21,57,59].…”

Section: Long-term Outcomesmentioning

confidence: 55%

“…Progression rates ranged from 10.8 to 24% [21,32 ▪▪ ,57–59], and were overall generally higher than in the adult studies. UDVA significantly improved in three studies [32 ▪▪ ,55,58], while no significant change was noted in an additional three [21,57,59]. BCVA or CDVA was significantly improved in four studies [32 ▪▪ ,57,58,59], with no significant change in three others [21,55,56].…”

Section: Long-term Outcomesmentioning

confidence: 55%

“…We reviewed seven studies examining long-term outcomes of SDP in the pediatric population (up to 18 years of age), with a follow-up range of 2-10 years [ ] and with no significant change in four others [21,56,57,59].…”

Section: Standardmentioning

confidence: 99%

“…We reviewed seven studies examining long-term outcomes of SDP in the pediatric population (up to 18 years of age), with a follow-up range of 2–10 years [21,32 ▪▪ ,55–59]. Five studies listed post-CXL progression criteria, including an increase in Kmax of at least 1 or 1.5 D at the most recent follow-up.…”

Section: Long-term Outcomesmentioning

confidence: 99%

“…21,32 && ,[55][56][57][58][59]. Five studies listed post-CXL progression criteria, including an increase in Kmax of at least 1 or 1.5 D at the most recent followup.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Long-term outcomes of corneal crosslinking

Cehelyk,

Syed

2024

Current Opinion in Ophthalmology

View full text Add to dashboard Cite

Purpose of review This manuscript summarizes contemporary research from 2018 to 2023 evaluating long-term (≥2 years) outcomes of corneal crosslinking (CXL) for progressive keratoconus (KCN). Recent findings The standard Dresden protocol (SDP) has been utilized clinically since the early 2000 s to treat ectatic disorders, primarily progressive KCN and postrefractive ectasia. Various modifications have since been introduced including accelerated and transepithelial protocols, which are aimed at improving outcomes or reducing complications. This review summarizes data demonstrating that the SDP halts disease progression and improves various visual and topographic indices (UDVA, CDVA, Kmax, K1, K2) up to 13 years postoperatively. Accelerated and transepithelial protocols have been found to be well tolerated alternatives to SDP with similar efficacy profiles. Studies focusing on pediatric populations identified overall higher progression rates after CXL. All protocols reviewed had excellent safety outcomes in adults and children. Summary Recent studies revealed that SDP successfully stabilizes KCN long term, and a variety of newer protocols are also effective. Pediatric patients may exhibit higher progression rates after CXL. Further research is required to enhance the efficacy and ease of these protocols.

show abstract

Section: Long-term Outcomesmentioning

confidence: 55%

Section: Long-term Outcomesmentioning

confidence: 55%

Section: Standardmentioning

confidence: 99%

Section: Long-term Outcomesmentioning

confidence: 99%

“…21,32 && ,[55][56][57][58][59]. Five studies listed post-CXL progression criteria, including an increase in Kmax of at least 1 or 1.5 D at the most recent followup.…”

mentioning

confidence: 99%

See 3 more Smart Citations